Alimera科学 ALIM 深 沪
已收盘 09-16 16:00:00 美东时间
5.54
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 5.54
- 总市值 3879.66万
- 52周最高 5.65
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.6063
- 委 比 0.00%
- 总股本 700.30万
- 历史最高 131.55
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
Altimmune announces oral and three poster presentations on pemvidutide at ADA 2025 in Chicago from June 20-23. Pemvidutide, a GLP-1/glucagon dual receptor agonist, targets MASH, obesity, AUD, and ALD. Presentations will explore effects on cardiometabolic health, cardiovascular safety, and lipid metabolism.
06-13 11:30
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis
Alumis Inc. announced the completion of patient enrollment in its Phase 3 ONWARD clinical program for ESK-001, a potential treatment for moderate-to-severe plaque psoriasis. Over 1,700 patients were enrolled, with topline results expected in early Q1 2026.
05-29 11:55
Alumis Completes Merger with ACELYRIN
Alumis Inc. completes merger with ACELYRIN Inc., offering 0.4814 Alumis shares per ACELYRIN share. ACELYRIN stock ceases trading. The merger strengthens Alumis' balance sheet, enabling advancement of its late-stage pipeline through 2027.
05-21 13:10
